As of November 6, 2026, Compass Therapeutics, Inc. is a publicly traded company (Nasdaq: CMPX). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 8.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Tang Capital Management, LLC (9.99%), Suvretta Capital Management, LLC (8.2%), State Street (5.5%) (Schedule 13D/A, August 15, 2025).
Is this your company?
About to sign with, pay or invest in Compass Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Compass Therapeutics, Inc. a real, registered company?
- Compass Therapeutics, Inc. files with the SEC under CIK 1738021 (its SEC filings).
- Its shares are listed under the ticker CMPX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Compass Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-08-07).
Who are Compass Therapeutics, Inc.'s owners and officers?
Compass Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Vivo Opportunity Fund Holdings, L.P. | 4% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.5% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 4.3% |
| Schedule 13G/A, 2026-02-13 | Blackstone Alternative Asset Management Associates LLC | 3.4% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.2% |
| Schedule 13G/A, 2025-11-14 | Tang Capital Management, LLC | 9.99% |
| Schedule 13G/A, 2025-11-14 | Tang Capital Management, LLC | 9.99% |
| Schedule 13G, 2025-11-14 | Vivo Opportunity Fund Holdings, L.P. | 5.1% |
| Schedule 13G, 2025-10-29 | Bvf Partners L P/Il | 5.1% |
| Schedule 13G/A, 2025-08-21 | Suvretta Capital Management, LLC | 8.2% |
| Schedule 13D/A, 2025-08-18 | Commander Aggregator, LP | 4.5% |
| Schedule 13D/A, 2025-08-15 | Orbimed Advisors LLC | 8.9% |
Questions about who owns Compass Therapeutics, Inc.
Who owns Compass Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Compass Therapeutics, Inc.: Tang Capital Management, LLC (9.99%, Schedule 13G/A, filed 2025-11-14), Orbimed Advisors LLC (8.9%, Schedule 13D/A, filed 2025-08-15), Suvretta Capital Management, LLC (8.2%, Schedule 13G/A, filed 2025-08-21), State Street Corporation (5.5%, Schedule 13G, filed 2026-08-07) and Blackrock, Inc. (5.2%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Compass Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Compass Therapeutics, Inc. on this page are Tang Capital Management, LLC (9.99%), Orbimed Advisors LLC (8.9%) and Suvretta Capital Management, LLC (8.2%).
When did Tang Capital Management, LLC buy into Compass Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Compass Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Compass Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Compass Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Compass Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 6,603,336 shares (3.7% of shares outstanding) (Form 4, 2026-02-10).
- , the chief financial officer: 525,000 shares (0.29% of shares outstanding) (Form 4, 2026-01-05).
- , the chief accounting officer: 420,000 shares (0.23% of shares outstanding) (Form 4, 2026-10-02).
- , the general counsel: 196,000 shares (0.11% of shares outstanding) (Form 4/A, 2026-04-30).
Shares outstanding: 180,087,915 as of 2026-07-28, from the company's latest SEC cover page.
How much has Compass Therapeutics, Inc. raised?
No fundraising or offering filing from Compass Therapeutics, Inc. is on file with us.
Keep reading
More on Compass Therapeutics, Inc. and the records around it.
Compass Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), Context Therapeutics Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026)
- Blackstone Annex Master Fund L.P. also filed stake reports on 7 other companies: Corebridge Financial, Inc. (Nov 2026), Jersey Mike's Subs Inc. (Nov 2026), VARAGON CAPITAL CORPORATION (Oct 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Pasithea Therapeutics Corp. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/compass-therapeutics